RC
TXG icon

Renaissance Capital’s 10x Genomics TXG Stock Holding History

Renaissance Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-41,072
Closed -$1.86M – 85
2022
Q2 		$1.86M Buy
41,072
+14,546
+55% +$755K 0.99% 30
2022
Q1 		$2.02M Sell
26,526
-7,942
-23% -$695K 0.86% 33
2021
Q4 		$5.13M Sell
34,468
-5,604
-14% -$858K 1.32% 24
2021
Q3 		$5.83M Sell
40,072
-57,209
-59% -$9.82M 1.18% 23
2021
Q2 		$19.1M Buy
97,281
+17,763
+22% +$3.21M 3.01% 11
2021
Q1 		$14.4M Sell
79,518
-27,824
-26% -$4.8M 2.13% 14
2020
Q4 		$15.2M Buy
+107,342
New +$15.6M 2.08% 13

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Capital's TXG Position: Q3 2022 in Review

Renaissance Capital sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 41,072 shares — an estimated $1.86M sold.

Renaissance Capital first reported a position in TXG in Q4 2020 and held it in 7 quarters. The position peaked at $19.1M in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

  • Renaissance Capital reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
  • Renaissance Capital sold 41,072 10x Genomics shares in Q3 2022, an estimated $1.86M.
  • Renaissance Capital first reported a position in 10x Genomics in Q4 2020 and held it in 7 quarters.
  • Renaissance Capital's 10x Genomics position peaked at $19.1M in Q2 2021.
  • 233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Renaissance Capital's 13F filing for Q3 2022, filed 6 Oct 2022.